Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)
2017-003236-37Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in dyslipidemia, hypercholesterolemia, non–ST-segment elevation acute coronary syndrome (NSTE-ACS), sponsored by Amgen. Started Sep 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
dyslipidemiahypercholesterolemianon–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on 2017-003236-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003236-37.